Collagen VI is a crucial extracellular matrix protein composed of three alpha chains (α1. α2. α3) encoded by the *COL6A1*, *COL6A2*, and *COL6A3* genes. It assembles into a unique microfibrillar network, providing structural support and regulating cellular processes like adhesion, migration, and signaling. Primarily expressed in muscles, skin, and cartilage, Collagen VI is vital for maintaining tissue integrity and homeostasis.
Antibodies targeting Collagen VI are essential tools in studying its expression, distribution, and role in diseases. Mutations in Collagen VI genes cause muscular disorders such as Bethlem myopathy and Ullrich congenital muscular dystrophy, characterized by muscle weakness and joint contractures. These antibodies enable detection of abnormal Collagen VI deposition in patient tissues, aiding diagnosis and mechanistic studies. Additionally, Collagen VI dysregulation is linked to fibrosis, cancer progression, and impaired wound healing. Researchers use Collagen VI antibodies in techniques like immunohistochemistry, Western blotting, and ELISA to explore its involvement in extracellular matrix remodeling, tumor microenvironment interactions, and therapeutic targeting.
Monoclonal and polyclonal Collagen VI antibodies are commercially available, often validated for specificity across species. Their applications extend to preclinical models, where they help evaluate Collagen VI’s contribution to disease pathology or tissue regeneration. As interest grows in matrix biology, Collagen VI antibodies remain pivotal in advancing both basic research and clinical diagnostics.